Structure-activity relationship for human cytochrome P450 substrates and inhibitors

Drug Metabolism Reviews

Volumn 34, Issue 1-2, 2002, Pages 69-82

  Lewis, David F V ^a   Modi, Sandeep ^b   Dickins, Maurice ^b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 1 METHYL 6 PHENYLIMIDAZO[4,5 B]PYRIDINE; 2 AMINO 3 METHYLIMIDAZO[4,5 F]QUINOLINE; 2 AMINO 3,8 DIMETHYLIMIDAZO[4,5 F]QUINOXALINE; 3,5 DIMETHYL 2 (3 PYRIDYL) 4 THIAZOLIDINONE; 4 BIPHENYLAMINE; AFLATOXIN B1; CAFFEINE; CHLORZOXAZONE; COTININE; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DEBRISOQUINE; ERYTHROMYCIN; ETHOXYRESORUFIN; LOSIGAMONE; MEPHENYTOIN; NICOTINE; PHENACETIN; TACRINE; THEOPHYLLINE; TOLBUTAMIDE; UNINDEXED DRUG;

ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG OXIDATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENZYME SUBSTRATE COMPLEX; HUMAN; HYDROGEN BOND; PHARMACOGENETICS; STRUCTURE ACTIVITY RELATION;

CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, FACTUAL; ENZYME INHIBITORS; HUMANS; KINETICS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036223228     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-120001391     Document Type: Article

References (28)

1. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature
2. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers and inhibitors
3. Human cytochrome P450s: Selectivity and measurement in vivo
4. Human cytochrome P450 enzymes
5. Structural determinants of P450 substrate specificity
6. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics
7. Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles
8. Modeling human cytochromes P450 for evaluating drug metabolism
9. Cytochrome P450 substrates specificities, substrate structural templates and enzyme active site geometries
10. Pharmacophore and three-dimensional quantitative structure-activity relationship methods for modeling cytochrome P450 active site
11. Properties of cytochrome P450 isoenzymes and their substrates. Part 1: Active site characteristics
12. Properties of cytochrome P450 isoenzymes and their substrates. Part 2: Properties of cytochrome P450 substrates
13. Molecular modeling of CYP1 family enzymes CYP1A1, CYPIA2, CYP1A6 and CYP1B1 based on sequence homology with CYP102
14. Moleculer modeling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity
15. 5 binding site and comparisons with CYP2B1 and CYP2B4
16. Molecular modeling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: Rationalization of enzyme specificity and site-directed mutagenesis experiments in the CYP2C subfamily
17. Molecular modeling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: Structural studies on specific CYP2D6 substrate metabolism
18. Molecular modeling of human CYP2E1 by homology with the CYP102 hemoprotein domain: Investigation of the interactions of substrates and inhibitors within the putative active site of the human CYP2E1 isoform
19. Molecular modeling of CYP3A4 from an alignment with CYP102: Identification of Key interactions between putative active site residues and CYP3A-specific chemicals
20. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity
21. Advances in in vitro drug metabolism screening
22. The P450 catalytic cycle and oxygenation mechanism
23. cam, at atomic resolution
24. Interactions between redox partners in various cytochrome P450 systems: Functional and structural aspects